The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 2 June 2003. doi:10.1084/jem.20021820
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 322K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, J.-D.
Right arrow Articles by Ivashkiv, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, J.-D.
Right arrow Articles by Ivashkiv, L. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/6/1573 $5.00
The Journal of Experimental Medicine, Volume 197, Number 11, 1573-1583

Inhibition of Interleukin 10 Signaling after Fc Receptor Ligation and during Rheumatoid Arthritis

Jong-Dae Ji1, Ioannis Tassiulas1, Kyung-Hyun Park-Min2, Ani Aydin1, Ingrid Mecklenbräuker3, Alexander Tarakhovsky3, Luminita Pricop1, Jane E. Salmon1,2 and Lionel B. Ivashkiv1,2

1 Department of Medicine Hospital for Special Surgery, Weill Graduate School of Medical Sciences of Cornell University
2 Graduate Program in Immunology, Weill Graduate School of Medical Sciences of Cornell University
3 Laboratory of Lymphocyte Signaling, The Rockefeller University, New York, NY 10021

Address correspondence to Lionel B. Ivashkiv, Hospital for Special Surgery, 535 East 70th St., New York, NY 10021. Phone: 212-606-1653; Fax: 212-774-2337; E-mail: ivashkivl{at}hss.edu

Interleukin-10 (IL-10) is a potent deactivator of myeloid cells that limits the intensity and duration of immune and inflammatory responses. The activity of IL-10 can be suppressed during inflammation, infection, or after allogeneic tissue transplantation. We investigated whether inflammatory factors suppress IL-10 activity at the level of signal transduction. Out of many factors tested, only ligation of Fc receptors by immune complexes inhibited IL-10 activation of the Jak-Stat signaling pathway. IL-10 signaling was suppressed in rheumatoid arthritis joint macrophages that are exposed to immune complexes in vivo. Activation of macrophages with interferon-{gamma} was required for Fc receptor–mediated suppression of IL-10 signaling, which resulted in diminished activation of IL-10–inducible genes and reversal of IL-10–dependent suppression of cytokine production. The mechanism of inhibition involved decreased cell surface IL-10 receptor expression and Jak1 activation and was dependent on protein kinase C delta. These results establish that IL-10 signaling is regulated during inflammation and identify Fc receptors and interferon-{gamma} as important regulators of IL-10 activity. Generation of macrophages refractory to IL-10 can contribute to pathogenesis of inflammatory and infectious diseases characterized by production of interferon-{gamma} and immune complexes.

Key Words: interleukin 10 • Fc receptor • signal transduction • Jak-Stat • macrophage


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS